Venlafaxine is named as an intervention in 3 current clinical trials in our China and India registers. 3 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is All India Institute of Medical Sciences, Bhubaneswar (1). The most-studied condition is Somatic Symptom Disorder (DSM-V).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Effect of Venlafaxine Versus Dosulepin in Pain Predominant Somatic Symptom Disorder
NCT06803485 · Somatic Symptom Disorder (DSM-V)
|
Phase 4 | Recruiting | All India Institute of Medical Sciences, Bhubaneswar | India |
|
Pragmatic Trial of Obsessive-compulsive Disorder
NCT04539951 · ClinicalTrials.gov ↗ · Obsessive-Compulsive Disorder
|
Phase 2 | Recruiting | Shanghai Mental Health Center | China |
|
Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder
NCT07330648 · ClinicalTrials.gov ↗ · Generalized Anxiety Disorder
|
Phase 2 | Recruiting | Anhui Medical University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
29 single-substance products containing Venlafaxine on the HPRA medicines list.
No entry for Venlafaxine in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| All India Institute of Medical Sciences, Bhubaneswar | 1 |
| Anhui Medical University | 1 |
| Shanghai Mental Health Center | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
| Clinical trials in India | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China and India registers name Venlafaxine as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 3 trials are recruiting: 2 with sites in China and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
All India Institute of Medical Sciences, Bhubaneswar (1), Anhui Medical University (1) and Shanghai Mental Health Center (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 29 single-substance products containing Venlafaxine, for example Efexor XL 150 mg prolonged-release capsules, hard (Viatris Healthcare Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Venlafaxine has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Venlafaxine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Venlafaxine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Venlafaxine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.